When the US FDA approved a de novo application for an irregular rhythm notification feature for Apple Watch Series 4 in record time, it did so despite the application not meeting its primary endpoint. The agency says that while it missed the mark on the first endpoint, regulators approved the de novo based on the secondary endpoint and other analyses.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?